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Abstract
Background: Evidence-based guidelines concerning the older head and neck cancer (HNCA) patient are lacking.
Accurate patient selection for optimal care management is therefore challenging. We examined if geriatric
assessment is indicative of long-term health-related quality of life (HRQOL) and overall survival in this unique
population.
Methods: All HNCA patients, aged ≥65 years, eligible for curative radio(chemo)therapy were evaluated with the
Geriatric-8 (G-8) questionnaire and a comprehensive geriatric assessment (CGA). Euroqol-5 dimensions (EQ-5D) and
survival were collected until 36 months post treatment start. Repeated measures ANOVA was applied to analyse
HRQOL evolution in ‘fit’ and ‘vulnerable’ patients, defined by G-8. Kaplan-Meier curves and cox proportional hazard
analysis were established for determination of the prognostic value of geriatric assessments. Quality-adjusted survival
was calculated in both patient subgroups.
Results: One hundred patients were recruited. Seventy-two percent of patients were considered vulnerable
according to CGA (≥2 abnormal tests). Fit patients maintained a relatively acceptable long-term HRQOL, whilst
vulnerable patients showed significantly lower median health states. The difference remained apparent at 36 months.
Vulnerability, as classified by G-8 or CGA, came forward as independent predictor for lower EQ-5D index scores. After
consideration of confounders, a significantly lower survival was observed in patients defined vulnerable according to
G-8, compared to fit patients. A similar trend was seen based on CGA. Calculation of quality-adjusted survival showed
significantly less remaining life months in perfect health in vulnerable patients, compared to fit ones.
Conclusions: G-8 is indicative of quality-adjusted survival, and should be considered at time of treatment decisions for
the older HNCA patient.
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Background
Head and neck cancer (HNCA) ranks the sixth most
common cancer worldwide, with more than half a mil-
lion diagnoses each year [1, 2]. Globally, approximately
half of HNCA patients are 65 years or older at diagnosis,
and their numbers are even increasing [3]. Despite re-
cent progress in the management of HNCA, benefits in
overall survival have been associated with increased
therapy-related morbidity persisting for up to 12 to
36 months after treatment, and adversely affecting pa-
tients’ health-related quality of life (HRQOL) [4–7].
Treatment decisions for the older HNCA population
are challenging since evidence-based guidelines from large
randomised-controlled trials (RCTs) are lacking due to ex-
clusion of the older patient based on age or co-morbidities
[3, 8–10]. Treatment delivered to older HNCA patients
has been reported to comply with the institutions policy
in less than 50 % of cases [11]. Although radiochemother-
apy is considered as an intensive treatment in oncology
patients, at present, there are only few tools available that
integrate functional factors to adequately select eligible
older patients. Since mid-1990 implementation of Com-
prehensive Geriatric Assessment (CGA) has been sug-
gested by multiple international cancer networks, as a key
treatment approach for all patients aged 70 years and
older at time of diagnosis [12–15]. A CGA is described
as a multidimensional test battery that screens for im-
pairment in different age-related domains including
co-morbidity, function, physical performance, cogni-
tion, nutrition, emotional status, polypharmacy, social
support and living environment [16]. Several trials
have reported the value of CGA in discovering geriat-
ric problems, as well as to predict treatment toler-
ance, morbidity and mortality in mixed oncology
settings based on their functional age. The time and
resource requirements associated with performing
CGA, however, have hindered implementation in daily
practice [17]. Though, recently, the short Geriatric-8
(G-8) screening instrument was reported to have on
its own the capacity to identify vulnerable patients
and showed prognostic value for functional decline
and overall survival in a mixed oncology population
[18]. Our research team validated the G-8 for use in
the HNCA population [19]. Moreover, we reported ser-
ial CGA to be indicative for HRQOL before and during
treatment, and suggest its use to guide supportive care
management during radiochemotherapy [20].
In light of the late toxicity often associated with radio-
chemotherapy [21, 22], the impact on daily functioning
or thus patients’ HRQOL, might be more important to
examine in an older HNCA population than the meas-
urement of the classical hard end-points, such as
disease-free or overall survival. Moreover, stratification
of the older population into ‘fit’ and ‘vulnerable’ patients,
based on geriatric assessments, could provide more reli-
able results about treatment tolerability and long-term
outcome in these specific patient subgroups [23]. Previ-
ous studies have assessed long-term HRQOL in HNCA
patients [24–28], however, to our knowledge, no study
provided HRQOL based on subgroups distinguished by
geriatric assessments for the older HNCA patient treated
with curative intended radiochemotherapy.
This prospective trial was, therefore, designed to docu-
ment the HRQOL, through the EuroQol-5 dimensions
(EQ-5D) questionnaire, in both ‘fit’ and ‘vulnerable’ older
HNCA patients from treatment start to long-term
follow-up. Moreover, we also aimed to analyse the value
of geriatric assessments to predict long-term HRQOL,




The trial involved older cancer patients, aged ≥65 years,
with a histologically confirmed diagnosis of squamous
cell carcinoma of the head and neck, eligible for curative
primary or adjuvant radiotherapy, with or without con-
comitant systemic therapy. Tumours of the parotid
gland or nasal cavity and paranasal sinuses were ex-
cluded. Other exclusion criteria were: distant metastases,
another non-cured cancer, except for a squamous or
basal cell carcinoma of the skin, and inability for ad-
equate communication in Dutch or French. Patients
were consecutively recruited from January 2010 until
April 2012 upon presentation at the departments of ra-
diation oncology at the General Hospital Groeninge
(Kortrijk, Belgium) and the Ghent University Hospital
(Ghent, Belgium) [19, 20]. The majority of patients were
treated with intensity-modulated radiation therapy at a
dose of 2.0 Gy per day, 5 days per week, for a total dose
of 70 Gy in the primary, or 66 Gy in the adjuvant set-
ting. Ten patients received conformal radiotherapy be-
cause of their poor general condition. Chemotherapy
varied between weekly (40 mg/m2) or 3-weekly cisplatin
(100 mg/m2) or weekly cetuximab (start dose of 400 mg/
m2 one week prior to radiation therapy, followed by
weekly 250 mg/m2) depending on their general condi-
tion and the treatment centre. Written informed consent
was obtained from all included patients. The trial was
approved by the Ethics Committees of the Ghent Uni-
versity Hospital (Ghent, Belgium) and the General Hos-
pital Groeninge (Kortrijk, Belgium).
Study design
An observational, multicentre, prospective study was
performed. Patients were assessed with the Vulnerable
Elders Survey-13 (VES-13) and the G-8 questionnaire,
two screening tools [29, 30], and a full CGA as the gold
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standard, once before initiation of treatment (Week 0,
W0), and again during the 4th week (W4) of their treat-
ment. In accordance with previous research, patients
exhibiting no impairments or in only one domain within
CGA were defined as ‘fit’ whilst patients exhibiting im-
pairments in two or more domains within the CGA were
defined as ‘vulnerable’ [19, 31–33]. The measures within
the CGA tool are outlined in two prior publications per-
formed by our research team [19, 20]. Since the initi-
ation of our clinical trial in January 2010, the value of
the VES-13 for use in the older population has been
questioned [34, 35]. Moreover, it showed low sensitivity
in the identification of vulnerable older HNCA patients
[19]. For that reason, classification of patients by VES-13
was not included in the current analysis. The G-8, on
the contrary, has been validated by several independent
researchers in a mixed oncology population, and more
specifically – by our own research team – in the target
population [17, 19, 36]. Moreover, its prognostic value
has been demonstrated in a mixed oncology population
[18, 37]. Patients scoring 14 or less out of 17 on the G-8,
were considered vulnerable.
At both time-points the EQ-5D questionnaire, as a
measure of HRQOL, was self-completed or completed
through patient interview when required. In addition, it
was completed through a postal survey at 2, 5, 12, 24
and 36 months (M) after treatment start. A patient flow-
chart is presented in Fig. 1.
The EQ-5D is one of the most commonly used generic
questionnaires to measure HRQOL, and has been devel-
oped by the EuroQol Group [38, 39]. It enables a self-
reported description of the subjects’ current health in
five dimensions i.e., mobility, self-care, usual activities,
pain/discomfort and anxiety/depression. The subject is
asked to grade their own current level of function in
each dimension into one of three degrees of disability
(severe, moderate or none). The combination of these
with the conditions “death” and “unconscious” enables
description of 245 different health states.
We applied the mathematical representation of the
model developed by Cleemput, which was based on 25
health states that were obtained by 548 Flemish (Belgian)
respondents included in the final dataset [40]. Based on
this model, for each health state an utility score can be
deducted, called the EQ-5D index score, which repre-
sents the patients’ description of their own health and
how this health state relates to the health state of the
general population [38, 41]. A score of 1 indicates per-
fect health, 0 indicates death. Negative scores indicate
‘worse than death’, and represent health states where pa-
tients experience at least severe disability in three di-
mensions, in combination with moderate or severe
disability in the remaining dimensions.
Baseline demographic data, clinical characteristics, de-
tails of their medical history, therapy regimen, and over-
all survival were collected through the medical records.
Statistical analysis
Demographic, oncological, geriatric, HRQOL and sur-
vival data were analysed descriptively. Classification
of patients as ‘fit’ or ‘vulnerable’ was based on base-
line (W0) CGA or G-8 assessments. Repeated mea-
sures ANOVA were applied to evaluate the difference
in HRQOL evolution, measured with the EQ-5D
questionnaire, between both ‘fit’ and ‘vulnerable’ pa-
tients, and corrected for confounders such as age,
gender, civil state, living situation, tumour diagnosis,
tumour stage, and applied treatment. Spearman corre-
lations were performed to indicate potential correlations
between EQ-5D index scores, G-8, and the number of ab-
normal tests within CGA. Kaplan-Meier curves were
established to analyse the prognostic value of patient clas-
sification based on G-8 and CGA. A cox proportional haz-
ard analysis was performed to confirm the prognostic
Fig. 1 Patient flowchart. Abbreviations: W, week; CVA, cerebrovascular accident
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value of the different geriatric assessments, after correc-
tion for confounders such as age, gender, civil state,
tumour diagnosis, tumour stage, and applied treatment.
Variables were selected by backward elimination. Quality-
adjusted survival within 36 months of follow-up was cal-
culated for evaluation of the HRQOL in the remaining life
months, and Mann–Whitney U test was applied for com-
parison between both subgroups. Quality-adjusted life
months were calculated through resolution of the follow-
ing integral: QALY = ∑ ∫ Ps(t)Qs(t)dt where Ps(t) represents
the probability of survival, and Qs(t) represents the
HRQOL [42], measured with the EQ-5D index score, at
the seven different evaluation time points.
All analyses were performed using Prism® software
(GraphPad Prism 5, Inc., La Jolla, CA) and SPSS or SAS
software (version 20; IBM SPSS Statistics, Chicago, IL;
Table 1 Demographic and oncological characteristics of the study population
Study population Fit patientsa Vulnerable patientsa
N = 100 N = 32 N = 68
Demographic characteristics Median (range)
Age 72.0 (65.0– 86.0) 72.0 (65.0–84.0) 72.0 (65.0–86.0)
%
Gender
Male 86 28 58
Female 14 4 10
Social status
Married/living together 72 27 45
Profession
Labourer 44 12 32
Employee 31 8 23
Self-employed 25 12 13
Clinical characteristics
Tumour location
Oral cavity 15 3 12
Oropharynx 22 6 16
Hypopharynx 10 0 10
Nasopharynx 2 0 2
Supraglottis 18 4 14
Glottis 24 14 10
Subglottis 3 1 2
Occult primary 6 4 2
Tumour stage
Early stage (I-II) 31 15 16
Late stage (III-IVb) 69 17 52
Therapy initiation
Primary radiotherapy
Alone 40 14 26
With chemotherapy (cisplatin) 21 8 13
With biotherapy (cetuximab) 8 1 7
Adjuvant radiotherapy
Alone 21 7 14
With chemotherapy (cisplatin) 8 2 6
With biotherapy (cetuximab) 2 0 2
aclassification according to G-8, assessed at W0
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version 9.3; SAS Institute Inc., Cary, NC, USA). Statis-
tical significance was assumed when P < 0.05. Since this
manuscript comprises (prespecified) secondary end-
points, all P-values should be considered as explorative,
and thus have a merely hypothesis-generating value.
Results
Study population characteristics
One hundred patients were recruited. An overview of
demographic and oncological characteristics is pre-
sented in Table 1.
Seventy-two percent of patients were considered
vulnerable, thereby presenting with at least two ab-
normal test results within the full CGA, assessed at
W0. Patients presented with deficiencies in two
(29 %), three (14 %), four (16 %), five (7 %) and all
but one (6 %) of the domains within CGA. Of the
28 % of patients who were defined fit, 8 % did not
show a single deficiency on one of the standardised
tests within CGA. The majority of patients presented
with severe-grade comorbidities (CIRS-G, 77 %), while
half of patients showed difficulties in community
functioning (IADL, 52 %) and nutritional parameters
(MNA, 48 %). Approximately one third of patients
showed problems with gait and balance (Tinetti,
29 %), and a quarter of patients did not succeed in
self-care (ADL, 16 %), or showed signs of cognitive
impairment (MMSE, 16 %) and depression (GDS,
17 %) [19, 20].
According to the G-8 (cut-off ≤14), 68 % of patients
were considered vulnerable. Patients showed a median
G-8 score of 13.0 (Q1,Q3: 10.0, 15.0), with a mini-
mum and maximum score of respectively 3.0 and
17.0. An overview of W0 and W4 CGA and G-8 data
is presented in Table 2.
Short- and long-term health-related quality of life
EQ-5D data, as a measure of HRQOL, was complete for
eighty-one patients. Nineteen patients had one or several
missing assessments due to several reasons that are re-
ported in Fig. 1. Post-treatment EQ-5D postal response
was 90 %.
In general, a median EQ-5D index score of 0.66 (0.55,
0.76) was found for all patients prior to treatment start.
A deterioration of HRQOL, defined by EQ-5D, towards
a median score of 0.42 (0.26, 0.73) was reported during
mid-therapy (W4). Median scores increased again to-
wards baseline values 0.66 (0.29, 0.76) at end of treat-
ment (2 M). During follow-up evaluations, patients
reached median EQ-5D index scores of 0.66 (0.27, 0.76)
at 5 M, however, values slowly deteriorated thereafter
due to the increasing number of deaths (12 M: 0.64 (0.0,
0.76), 24 M: 0.29 (0.0, 0.76), and 36 M: 0.0 (0.0, 0.67)).
EQ-5D index scores for fit and vulnerable patients, as
classified by G-8, are presented in Table 3 and Fig. 2.
While fit patients regained baseline values at end of
treatment, vulnerable patients, on the contrary, showed
significantly lower EQ-5D index scores compared to fit
patients, as well before, during and after treatment start
(p < 0.05). Classification by CGA showed comparable re-
sults (data not shown).
As presented in Table 3, Spearman correlations
showed a statistically significant positive correlation be-
tween patients’ G-8 score and the EQ-5D index score at
different time-points before, during and after treatment
(P < 0.001). In accordance, a statistically significant nega-
tive correlation was found between the number of ab-
normal CGA domains and the corresponding EQ-5D
index score (P < 0.001).
Repeated measures ANOVA revealed a statistically sig-
nificant time-effect of EQ-5D index scores (P < 0.0001),
a significant effect of vulnerability as classified by G-8 or
Table 2 Vulnerability percentage of HNCA patients, assessed by CGA or G-8, at W0 and W4
Vulnerable patients at W0 Vulnerable patients at W4
(n = 100; %) (n = 87; %)
Geriatric-8 (G-8) 68.0 92.0
Comprehensive geriatric assessment (CGA) 72.0 83.9
Domains within CGA
Activities of Daily living (ADL) 16.0 18.4
Instrumental activities of daily living (IADL) 52.0 70.1
Mini nutritional assessment (MNA) 48.0 75.9
Mini mental state examination (MMSE) 16.0 17.4
Geratric depression scale (GDS) 17.0 28.7
Tinetti gait and balance (Tinetti) 29.0 34.5
Cumulative illness rating scale for geriatrics (CIRS-G) 77.0 78.2
Wweek
Adapted from Pottel et al. [20]
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the number of positive CGA domains at treatment start
(P < 0.0001), and a significant effect of advanced-stage
cancer (P < 0.001) as independent predictors of low
HRQOL values (Additional file 1: Table S1).
Prognostic value of geriatric assessments
Survival data were missing for four patients (Fig. 1).
Seven patients died during treatment or in the first week
after end of treatment. During follow-up, 10.4 %, 25.0 %,
40.6 % and 51.0 % of the total study population had died
at respectively 5, 12, 24 and 36 M. Median(Q1,Q3) sur-
vival was respectively 1095 days (1018, 1095) and
687 days (338, 1095) days for fit and vulnerable patients,
assessed with G-8.
Kaplan-Meier curves revealed a statistically significant
lower overall survival in patients defined vulnerable ac-
cording to G-8 (log-rank χ2 = 10.46, P < 0.01), compared
to fit patients. Likewise, a trend towards statistical sig-
nificant lower survival in vulnerable patients, compared
to fit patients was seen when defined by CGA (χ2 = 3.08,
p = 0.08) (Fig. 3).
Cox proportional hazard analysis indicated advanced-
stage cancer (P < 0.05) and vulnerability according to
G-8 (P < 0.01) as independent predictors of mortality
after curative radio(chemo)therapy. Within the model
for CGA, advanced-stage cancer (P < 0.001) and male
gender (P < 0.05) were predictive for mortality, but not
CGA (P = 0.12) (Additional file 2: Table S2).
Quality-adjusted survival
Calculation of the quality-adjusted survival within
36 M of follow-up showed significantly lower
remaining life months in perfect health in the vulner-
able (V) group, compared to the fit (F) group of pa-
tients, as classified by the G-8 (F: 23.3 (18.2, 27.4), V:
8.8 (2.8, 15.0), p < 0.0001) and full CGA (F: 21.8
(11.2, 25.4), V: 9.9 (3.8, 15.9), p < 0.001).
Discussion
Lack of evidence-based guidelines concerning appropri-
ate care for the older HNCA patient challenges treating
physicians in the trade-off between quality of life and
survival [3, 11]. Although implementation of geriatric
assessments has been proposed by several inter-
national cancer networks in latest years [13, 15, 43],
we were the first to examine the feasibility of per-
forming serial CGA during radiochemotherapy in this
target population [19, 20]. In the current final manu-
script on these data, we demonstrate - for the first
time - that vulnerable patients, as classified by G-8 or
CGA, show significantly lower HRQOL within their
remaining life months compared to fit patients. More-
over, our results are suggestive for G-8 as an inde-
pendent parameter for quality-adjusted survival.
At treatment initiation, approximately three quarter of
patients were defined vulnerable according to CGA. A
relatively low median EQ-5D index score of 0.66 was ob-
served at presentation. This could partly be explained by
the symptomatic, advanced-stage of the disease. Based
on CGA, and without taking potential confounders into
consideration, the proportion of fit or vulnerable pa-
tients was comparable in the early and advanced-stage
diseased groups. However, patients with an advanced-
stage cancer did show a significantly lower G-8 score
than early stage patients (P < 0.01, data not shown).
Since three of the eight questions in the G-8 question-
naire focus on nutritional problems, and advanced-stage
HNCA is often associated with malnutrition due to diffi-
culty of deglutition or mastication, G-8 might slightly
overestimate the proportion of vulnerable patients in
case of an advanced-stage cancer. However, in the multi-
variate survival and EQ-5D analysis the effect of G-8
remained significant, after correction for confounders
such as tumour stage.
In comparison, EQ-5D index scores ranging from 0.11
to 0.71 were described in literature for respectively older
institutionalised patients with dementia [44], to older pa-
tients receiving post-acute rehabilitation in an outpatient
[45] or day rehabilitation facility [46] setting. A significant
deterioration of health state was seen at mid-treatment.
Indeed, treatment is known to induce additional disability
[47, 48]. Moreover, prior work by our research team
Table 3 Short- and long-term health-related quality of life, represented by EQ-5D index score
W0 W4 2 M 5 M 12 M 24 M 36 M
EQ-5D index score [median (Q1, Q3)]
General 0.66 (0.55, 0.76) 0.42 (0.26, 0.73) 0.66 (0.29, 0.76) 0.66 (0.27, 0.76) 0.64 (0.0, 0.76) 0.29 (0.0, 0.76) 0.00 (0.00, 0.67)
Fita 0.76 (0.66, 0.76) 0.66 (0.39, 0.76) 0.74 (0.66, 0.76) 0.76 (0.66, 1.00) 0.76 (0.64, 1.00) 0.76 (0.32, 1.00) 0.66 (0.00, 1.00)
Vulnerablea 0.63 (0.29, 0.73) 0.39 (0.21, 0.67) 0.58 (0.23, 0.73) 0.66 (0.19, 0.76) 0.57 (0.00, 0.74) 0.00 (0.00, 0.66) 0.00 (0.00, 0.58)
Spearman correlations [rs]
b
G-8 0.64 0.42 0.41 0.42 0.52 0.45 0.38
Abnormal CGA domains −0.74 −0.46 −0.43 −0.45 −0.46 −0.34 −0.41
Wweek, M month, G-8 geriatric-8, EQ-5D euroqol-5 dimensions
aclassification based on G-8 assessed at W0, bspearman correlations between EQ-5D index score and respectively G-8 and the number of abnormal CGA domains
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showed a significant increase in the number of vulnerabil-
ities, as measured by CGA, at mid-treatment. Also, we
found that CGA is indicative of short-term HRQOL (dur-
ing treatment). Indeed, all patients defined as ‘vulnerable’
showed significantly lower functional status, and higher
symptom scores, as measured by EORTC QLQ C30 and
HN35 questionnaire, compared to their ‘fit’ counterparts
both prior to, and during treatment [20].
Although it is known that chronic radiation-induced
toxicities are common in this population, no literature
could be found regarding its impact on long-term
HRQOL in the older HNCA patient. To the best of
our knowledge, we are the first to provide data con-
cerning long-term HRQOL and overall survival in
subgroups of older HNCA patients, as classified by
geriatric assessments.
Our data demonstrate that fit patients obtained
HRQOL values comparable to baseline values already at
treatment end, while vulnerable patients only regained
their original health state at 5 months post treatment
start. Moreover, fit patients were able to maintain a
Fig. 2 Evolution of health-related quality of life, assessed by EQ-5D,
from treatment start to 36 months of follow-up. a-b Data presented
as boxplots, graphically displaying median, inter-quartile range and
minimum and maximum data values. c Data presented as mean ±
standard deviation. a Evolution of HRQOL, assessed by EQ-5D, in
‘fit’ older HNCA patients, as defined by G-8. b Evolution of
HRQOL, assessed by EQ-5D, in ‘vulnerable’ older HNCA patients,
as defined by G-8. c Evolution of HRQOL, assessed by EQ-5D, in
‘fit’ and ‘vulnerable’ older patients
Fig. 3 Overall survival, represented by Kaplan-Meier curves, of the
‘fit’ and ‘vulnerable’ older HNCA patient. a Overall survival of patients
classified as ‘fit’ or ‘vulnerable’, by G-8. b Overall survival of patients
classified as ‘fit’ or ‘vulnerable’, by CGA. Log-rank test was applied to
measure the difference between the curves
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median HRQOL index of 0.76 until 24 months. In vul-
nerable patients, on the contrary, a fast decline in
HRQOL was observed at one year onwards. Spearman
correlations confirmed that a higher vulnerability score,
based on CGA or G-8, was associated with a lower EQ-
5D index score at all evaluated time points. In compari-
son, Ramaekers et al. reported an average EQ-5D index
of 0.85 at 6 months post radio(chemo)therapy in 396
HNCA patients of all ages with no evidence of recurrent
disease [28]. Although HRQOL is a very subjective mat-
ter, Kvamme et al. reported that cut-off points around
0.65–0.70 for the EQ-5D questionnaire indicate an ac-
ceptable health state across diseases [49]. According to
this definition, the overall long-term HRQOL scores re-
ported by vulnerable patients could thus be considered
unacceptable. Since an EQ-5D index of “0” was assigned
to patients who had died, the median health index repre-
sents an accurate reflection of the total population, un-
biased by survivorship effects. Indeed, median EQ-5D
index scores of the survivors range between 0.69–0.75
from 5 M post treatment initiation onwards. Surviving
vulnerable patients show a significant lower EQ-5D
index score at follow-up than their fit counterparts (data
not shown). Kaplan-Meier analyses confirmed the sig-
nificantly lower survival rate in patients defined vulner-
able based on G-8. Although only a trend was seen
between vulnerability according to CGA and lower sur-
vival, this could be explained by the cut-off of ≥2 posi-
tive tests within CGA that was used. There is at present
no consensus on CGA content or the associated cut-off
scores to categorise HNCA patients as fit, vulnerable or
frail. Patients alive at 36 M did show a significantly
lower number of positive CGA tests at treatment start,
as compared to deceased patients (p < 0.01, data not
shown). At 36 M, 64 % of vulnerable patients had died,
in comparison to 30 % of fit patients. This is in agree-
ment with prior publications reporting a prognostic
value for the G-8 tool in a mixed oncology population
[18, 37]. Moreover, the high mortality rate corresponds
with a 5-year-overall survival rate of 30 % in advanced-
stage HNCA patients of all ages, treated with curative
intent [50, 51].
In agreement with the parameters reported by Sanabria
et al. in an older HNCA population, we also found male
gender and advanced clinical stage as independent predic-
tors of mortality [52]. However, contrary to this publica-
tion, comorbidity was not retained in our cox
proportional hazard model. This could be partly explained
by the different use of comorbidity assessment tools. High
CIRS-G scores were seen in the majority of HNCA pa-
tients in our study, due to cardiovascular and respiratory
problems associated with tobacco and alcohol abuse.
Moreover, Extermann described functional status to be in-
dependent of comorbidity in an older cancer population
[53]. Also, at present, evidence for the prognostic value of
comorbidity has been considered inconsistent [54].
In addition to the significant survival difference ob-
served between both subgroups, quality-adjusted sur-
vival revealed that vulnerable patients – although treated
with curative intent – have less than 10 remaining life
months in perfect health, compared to approximately
24 months for fit patients. These data clearly state that
the length of survival has to be weighed against the qual-
ity of survival. Hence, HRQOL and factors that could in-
fluence HRQOL should be considered important
treatment outcomes when examining new treatment
regimens in the older HNCA population. Also, patients’
subjective assessment should always have a central role
upon any consideration of treatment.
The results of this trial should, however, be inter-
preted with caution, due to some study limitations.
First, there is at present no consensus on CGA con-
tent or its definition of ‘vulnerability’ [17]. The G-8
tool, however, has in the meantime been validated in
both a French mixed oncology population and the
target population in specific [19, 30]. Moreover, it has
been reported to have on its own the capacity to
identify vulnerable patients and showed prognostic
value for functional decline and overall survival in a
mixed oncology population [18]. Therefore, we mainly
focused on classification by G-8.
Second, because our objective was to measure the
impact of radio(chemo)therapy on HRQOL, baseline
geriatric assessments were performed prior to radi-
ation treatment start, irrespective of a primary or ad-
juvant treatment setting. All patients in an adjuvant
setting underwent surgery within approximately four
weeks of the geriatric assessment, which could have
had a possible impact on their general condition.
However, no significant difference in the proportion
of vulnerability, based on G-8 or CGA, could be
found between the primary and adjuvant treatment
subgroup (data not shown). Third, our population
was a relatively young elderly population, with a me-
dian age of 72 years old. Although NCCN guidelines
indicate 70 years of age as a clinically relevant break-
point, we included patients aged 65 or older at enrol-
ment [15]. This age was based on historical
categorisation, as well as the knowledge that HNCA
patients often present with a geriatric profile already
before the age of 70, due to their often significant co-
morbidities. Fourth, although the EORTC HRQOL
questionnaires have been validated internationally and
offer detailed information about both the functional
and symptomatic health status of HNCA patients, we
chose the EQ-5D questionnaire as a postal survey for
long-term follow-up [55–57]. A potential limitation of
the calculated EQ-5D index is that the value set on
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which the calculations are based, might not be repre-
sentative for the older HNCA population [58]. Indeed,
many HRQOL instruments have not been tailored to
the special requirements of the older patient [59].
The study population with a median age of 72 years
old, comprising both Flemish and Walloon patients,
could have different views on quality of life and death
compared to the healthy Flemish middle-aged popula-
tion used as a value set. However, the tool has been
reported to have good responsiveness [60] and was
suggested by Rogers et al. for use in the HNCA
population [27]. Moreover, since the EQ-5D only
comprises five short questions, we considered it more
suitable since it limits patient burden and in that way
also encourages response rates. Indeed, with a re-
sponse rate of 90 %, the numbers are significantly
higher than the 64 % that is considered an acceptable
response rate [27].
Fifth, the heterogeneity of treatment is common
practice in this population [3]. Each individual’s
treatment plan was discussed at the multidisciplinary
oncology consult, according to local hospital guide-
lines and the experience of the treating physicians,
who may or may not have been partly influenced by
the geriatric assessment. In our study population,
only a minority of early- and advanced-stage cancers
were treated in an adjuvant setting (respectively
12.9 % vs 39.1 %). According to Sanabria et al., who
reported that substandard treatment offered to oral
and oropharyngeal cancer patients led to lower over-
all and cancer-specific survival [61], the lower
quality-adjusted survival observed in vulnerable pa-
tients could also be related to an increased cancer-
specific death. However, no significant difference in
disease-related deaths (i.e. local recurrences, distant
metastases, or treatment-related chronic toxicity), nor
in applied chemotherapy or radiation therapy dose
could be found between both fit and vulnerable pa-
tients (data not shown).
In addition, although our data underscore the value
of geriatric assessments to indicate long-term
HRQOL, the heterogeneity of applied treatment regi-
mens impedes us from providing prospectively vali-
dated recommendations about integration of CGA in
optimal treatment planning [62]. Incorporation of
long-term HRQOL in a RCT setting, as is currently
being performed by Paillaud et al. [63], could provide
a cost-benefit measurement of CGA intervention in
the target population, through calculation of quality-
adjusted life years gained. Also, future phase II or III
oncology trials should take long-term HRQOL in dif-
ferent subgroups of the older patient into account, to
enable valid judgment regarding individual treatment
tolerance and cost-benefits for the healthcare
institution [23]. Finally, since HPV-status was un-
available for most patients at time of treatment, it
was not incorporated in the analysis as a confound-
ing factor [64]. Also, no data was collected regarding
late radiation-induced toxicities.
Conclusions
In conclusion, our data demonstrate that classification
of patients as fit or vulnerable, based on G-8, is indi-
cative of overall and quality-adjusted survival, and
should be integrated at time of treatment decision for
the older HNCA patient. Moreover, future clinical tri-
als should integrate long-term HRQOL as a surrogate
end-point in order to balance the trade-offs between
late treatment toxicities and expected survival in
stratified groups of the older HNCA population, as
classified by geriatric assessments.
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